Cargando empresa
Just reported
Q3 2026 results
From Immunome's results release of 9 de noviembre de 2026; its quarterly report has since been filed.
Revenue
Actual
0,00 US$
Guided
—
No guide given
EPS, GAAP
Actual
-0,76 US$
Guided
—
No guide given
Operating income, GAAP
Actual
-90,4M US$
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Immunome is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B US$A+
EXELExelixis, Inc.16,8B US$A+
JAZZJazz Pharmaceuticals plc15,5B US$A
TECHBIO-Techne Corp11,4B US$A+
HALOHalozyme Therapeutics, Inc.11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Research collaboration payments (historical)
Compite con
- MKKGYMerck KGaA (through SpringWorks Therapeutics)
- MRKMerck & Co.A
- Tamaño
- 364,3B US$
- Margen
- 3,6 %
- 2616CStone Pharmaceuticals
- NVSNovartisA
- Tamaño
- 306,3B US$
- Margen
- -0,1 %
- CATXPerspective Therapeutics
- Tamaño
- 114,3M US$
- Ratio Therapeutics
Qué vende6
Varegacestat
An investigational, once-daily pill being developed to treat desmoid tumors, which can grow into nearby tissue.
IM-1021
An experimental antibody-drug conjugate designed to carry cancer-killing medicine to cells with the ROR1 marker; it is being tested in people with lymphoma and solid tumors.
IM-1617
An experimental antibody-drug conjugate designed to target a receptor found on some solid tumors.
Mostrar 3 más
IM-3050
An experimental treatment that uses a molecule aimed at the FAP marker to deliver radioactive lutetium-177 to cells in solid tumors.
IM-1340
An experimental antibody-drug conjugate being developed for solid tumors, including some lung and prostate cancers.
IM-1335
An experimental antibody-drug conjugate being developed to treat solid tumors; its target has not been publicly named.
Quién se lo compra1
- AbbVie paid for research work under a collaboration agreement that ended in July 2025 (high confidence); Immunome has not reported product-sale customers.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Immunome relies on outside manufacturers for materials used in its named drug programs and expects to rely on them for future commercial supply.
- 2The IM-3050 clinical trial depends on third-party diagnostic radiotracer supply; its treatment also requires radioactive lutetium-177.
- 3Varegacestat is licensed from Bristol Myers Squibb, and Immunome owes that company royalties and potential milestone payments if the drug is developed and sold.
Qué podría salir mal
- 1Varegacestat has not received marketing approval; the Food and Drug Administration could reject its application or require more information before a decision.
- 2Immunome has no product-sale revenue, reports continuing losses, and expects to need additional financing to fund development and potential commercialization.
- 3Drug development results are uncertain: clinical trials may not show adequate safety or benefit, and early results may not predict later trial outcomes.
Estados financieros completos →
Sobre Immunome Inc.
Immunome develops medicines intended to treat cancer. Its main drug candidate, varegacestat, is an investigational pill for desmoid tumors; the company has submitted a marketing application in the United States. Its other experimental treatments include drugs designed to deliver cancer-killing medicine or radiation to tumors.
- Sede
- Exton, Pennsylvania, United States
- Fundada en
- 2006
- Cotiza en
- Nasdaq
- Cierre del ejercicio
- December 31
Construido a partir de los propios informes de Immunome Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
